Simcere Pharmaceutical Group
Form 6-K
March 11, 2013
Table of Contents

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

## FORM 6-K

$\qquad$

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934

# Simcere Pharmaceutical Group 

(Translation of registrant s name into English)

# Edgar Filing: Simcere Pharmaceutical Group - Form 6-K 

## Xuan Wu District, Nanjing

## Jiangsu Province 210042

## People s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

## Table of Contents

## SIMCERE PHARMACEUTICAL GROUP

## FORM 6-K

TABLE OF CONTENTS
Exhibit 99.1 Press Release ..... 4

## Table of Contents

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

## Simcere Pharmaceutical Group

By: /s/ Yushan Wan
Name:
Title:
Yushan Wan
Acting Chief Financial Officer
DATE: March 11, 2013

